• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与单独使用阿米替林治疗的患者相比,同时使用氟西汀和阿米替林联合治疗的患者中这两种药物的稳态动力学。

Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone.

作者信息

el-Yazigi A, Chaleby K, Gad A, Raines D A

机构信息

Biological and Medical Research Department, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, Kingdom of Saudi Arabia.

出版信息

J Clin Pharmacol. 1995 Jan;35(1):17-21. doi: 10.1002/j.1552-4604.1995.tb04740.x.

DOI:10.1002/j.1552-4604.1995.tb04740.x
PMID:7751409
Abstract

The steady-state kinetics of amitriptyline (AMI), fluoxetine (FLU), and their active metabolites nortriptyline (NTRIP) and norfluoxetine (NFLU) were studied in 15 patients treated once daily for long durations with 50 mg of AMI and 20 mg of FLU. These compounds were analyzed simultaneously in plasma by liquid chromatography. The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively. The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17). There was a significant correlation (P < 0.05) between Css of FLU and that of AMI or NTRIP. The Css and Css(m)/Css values obtained for AMI were higher (P < 0.056 and P < 0.0034, respectively) than those we observed in 10 patients treated solely with the same dose of AMI. The twofold increase in Css of AMI and ninefold increase in Css of NTRIP seem to be the result of inhibition of the metabolism of these compounds by FLU, particularly the ring hydroxylation. Norfluoxetine may have a small inhibitory influence on the metabolism of NTRIP but lacks this effect on the metabolism of AMI.

摘要

对15名长期每日服用50毫克阿米替林(AMI)和20毫克氟西汀(FLU)的患者,研究了阿米替林、氟西汀及其活性代谢产物去甲替林(NTRIP)和去甲氟西汀(NFLU)的稳态动力学。通过液相色谱法同时分析血浆中的这些化合物。AMI、NTRIP、FLU和NFLU的稳态浓度(Css)均值及标准误(SEM)分别为80.6(14.2)、52.6(10.3)、85.3(16.1)和90(13.6)纳克/毫升,AMI和FLU的表观口服清除率(CLor)分别为42.4(8.6)和14.9(2.5)升/小时。NTRIP/AMI的代谢产物/药物稳态浓度比(Css(m)/Css)为0.75(0.14),NFLU/FLU的该比值为1.27(0.17)。FLU的Css与AMI或NTRIP的Css之间存在显著相关性(P<0.05)。AMI的Css及Css(m)/Css值高于(分别为P<0.056和P<0.0034)我们在仅接受相同剂量AMI治疗的10名患者中观察到的值。AMI的Css增加两倍和NTRIP的Css增加九倍似乎是FLU抑制这些化合物代谢的结果,尤其是环羟基化。去甲氟西汀可能对NTRIP的代谢有轻微抑制作用,但对AMI的代谢没有这种作用。

相似文献

1
Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone.与单独使用阿米替林治疗的患者相比,同时使用氟西汀和阿米替林联合治疗的患者中这两种药物的稳态动力学。
J Clin Pharmacol. 1995 Jan;35(1):17-21. doi: 10.1002/j.1552-4604.1995.tb04740.x.
2
Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma.血浆中氟西汀、阿米替林、丙咪嗪及其活性代谢物去甲氟西汀、去甲替林和去甲丙咪嗪的液相色谱同步测定。
Ther Drug Monit. 1993 Aug;15(4):305-9. doi: 10.1097/00007691-199308000-00008.
3
Steady-state concentrations of amitriptyline and its metabolite nortriptyline in Saudi patients.沙特患者中阿米替林及其代谢产物去甲替林的稳态浓度。
Ther Drug Monit. 1987;9(1):6-10. doi: 10.1097/00007691-198703000-00002.
4
[A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents].[一例代谢相互作用病例:阿米替林、氟西汀与抗结核药物]
Therapie. 1994 Nov-Dec;49(6):509-12.
5
[Toxic tricyclic drug plasma level caused by fluoxetine].[氟西汀导致的三环类药物中毒血浆水平]
Psychiatr Prax. 1995 Nov;22(6):252-3.
6
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.由于多药耐药基因1a(mdr1a)P-糖蛋白基因破坏导致血脑屏障缺陷的小鼠,阿米替林而非氟西汀进入脑内的渗透率增加。
Neuropsychopharmacology. 2000 Apr;22(4):380-7. doi: 10.1016/S0893-133X(99)00095-0.
7
Amitriptyline metabolism in elderly depressed patients and normal controls in relation to hypothalamic-pituitary-adrenal system function.老年抑郁症患者和正常对照者中阿米替林代谢与下丘脑-垂体-肾上腺系统功能的关系。
J Clin Psychopharmacol. 1995 Aug;15(4):250-8. doi: 10.1097/00004714-199508000-00003.
8
Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine.细胞色素P450IID6 29/29千碱基野生型等位基因女性患者中阿米替林的血浆半衰期极长——与氟西汀存在缓慢可逆性相互作用
Ther Drug Monit. 1991 Nov;13(6):533-6. doi: 10.1097/00007691-199111000-00012.
9
The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study.氟西汀对抑郁症门诊患者多导睡眠图的影响:一项初步研究。
Neuropsychopharmacology. 1994 Apr;10(2):85-91. doi: 10.1038/npp.1994.10.
10
Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta.阿米替林和去甲替林在离体灌注人胎盘中的经胎盘转运
Psychopharmacology (Berl). 2001 Feb;153(4):450-4. doi: 10.1007/s002130000597.

引用本文的文献

1
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.预防性治疗偏头痛药物的药代动力学变异性。
CNS Drugs. 2017 May;31(5):389-403. doi: 10.1007/s40263-017-0430-3.
2
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.临床药物基因组学实施联盟指南(CPIC):CYP2D6 和 CYP2C19 基因型与三环类抗抑郁药剂量:2016 年更新。
Clin Pharmacol Ther. 2017 Jul;102(1):37-44. doi: 10.1002/cpt.597. Epub 2017 Feb 13.
3
Potentiation of Amitriptyline Anti-Hyperalgesic-Like Action By Astroglial Connexin 43 Inhibition in Neuropathic Rats.
星形胶质细胞缝隙连接蛋白 43 抑制增强阿米替林抗神经病理性痛作用。
Sci Rep. 2016 Dec 12;6:38766. doi: 10.1038/srep38766.
4
Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.遗传多态性对细胞色素介导的药物-药物相互作用的影响:一种通用方法。
AAPS J. 2013 Oct;15(4):1242-52. doi: 10.1208/s12248-013-9530-2. Epub 2013 Sep 12.
5
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.临床药物遗传学实施联盟指南:CYP2D6 和 CYP2C19 基因型与三环类抗抑郁药剂量
Clin Pharmacol Ther. 2013 May;93(5):402-8. doi: 10.1038/clpt.2013.2. Epub 2013 Jan 16.
6
Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.定量预测细胞色素 P450(CYP)2D6 介导的药物相互作用。
Clin Pharmacokinet. 2011 Aug;50(8):519-30. doi: 10.2165/11592620-000000000-00000.
7
Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies.临床实践中细胞色素P450 2D6/3A4抑制剂-底物对的联合处方。挪威初级药房数据的回顾性分析。
Eur J Clin Pharmacol. 2005 Apr;61(2):119-25. doi: 10.1007/s00228-004-0877-2. Epub 2005 Feb 4.
8
Pharmacokinetics of haloperidol: an update.氟哌啶醇的药代动力学:最新进展。
Clin Pharmacokinet. 1999 Dec;37(6):435-56. doi: 10.2165/00003088-199937060-00001.
9
Ritonavir-fluoxetine interaction.利托那韦-氟西汀相互作用。
Antimicrob Agents Chemother. 1999 Jul;43(7):1815. doi: 10.1128/AAC.43.7.1815.
10
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.利用体外和体内数据评估代谢性药代动力学相互作用的可能性。
Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004.